Best Hospitals for TAVR (Transcatheter Aortic Valve Replacement) in Chennai, India

Aortic stenosis (AS) is a progressive narrowing of the aortic valve orifice caused primarily by calcific degeneration in patients over 65, rheumatic disease in younger populations, or congenital bicuspid valve anomaly. As leaflet calcification advances, the valve area falls below 1.0 cm² (severe AS), forcing the left ventricle to generate supraphysiological pressures to maintain forward cardiac output. The resulting pressure overload triggers concentric left ventricular hypertrophy, diastolic dysfunction, subendocardial ischemia, and—if untreated—a median survival of only 2–3 years after symptom onset (angina, syncope, or heart failure). Doppler echocardiography classically demonstrates a mean gradient above 40 mmHg and a peak aortic jet velocity exceeding 4 m/s in the setting of preserved flow, confirming hemodynamically severe disease.

• ELIGIBILITY — CLINICAL INDICATIONS:
• Symptomatic severe aortic stenosis: aortic valve area (AVA) ≤1.0 cm² (indexed AVA ≤0.6 cm²/m²), mean gradient ≥40 mmHg, or peak jet velocity ≥4 m/s
• High or prohibitive surgical risk: STS-PROM score ≥8% or EuroSCORE II ≥6%, or presence of risk factors not captured by scores (porcelain aorta, chest radiation sequelae, hostile mediastinum, severe frailty)
• Intermediate surgical risk: STS-PROM 4–8% — Heart Team decision with shared patient preference
• Low surgical risk (STS-PROM <4%): increasingly offered TAVR per PARTNER 3 / Evolut Low Risk data, especially patients ≥65 years
• +18 more

TAVR technology has evolved through four generations, and the choice of device and access strategy is individualized by the Heart Team based on MDCT annular measurements, calcium distribution, coronary anatomy, and patient vascular access.

Access ROUTES:

• Transfemoral (TF) Access [Preferred — >90% of cases]: A 14–18 French delivery sheath is introduced percutaneously via the common femoral artery under ultrasound guidance. Completely percutaneous closure using two pre-deployed ProGlide or MANTA vascular closure devices has eliminated the need for surgical cutdown in most patients. TF-TAVR is associated with the shortest procedure times, lowest bleeding rates, and fastest recovery — it is the default route when iliofemoral diameters exceed 5.5 mm and calcification is acceptable.
• Transaxillary / Subclavian Access: Used when femoral access is prohibitive; the delivery system is introduced via the axillary or subclavian artery. Requires careful assessment of vessel diameter (≥6 mm) and proximity to internal mammary grafts in post-CABG patients.
• Transcaval Access: A novel approach where the delivery system crosses from the inferior vena cava to the aorta via an electrosurgical puncture, sealed post-deployment with a nitinol plug; used at experienced centers when all arterial routes are unfeasible.
• Transapical (TA) / Transaortic (TAo) Access: Surgical approaches requiring a mini-thoracotomy or mini-sternotomy; reserved for patients with no suitable vascular access and performed by hybrid cardiac surgery teams. Associated with higher morbidity than TF access.

VALVE TECHNOLOGIES:

PHASE 1 — REMOTE CONSULTATION & CASE REVIEW (Weeks 1–2 before travel):

• Patient submits medical records (echocardiography reports, CT scans, coronary angiography, clinical notes) to GAF Healthcare's medical concierge team.
• Records are reviewed by a senior interventional cardiologist at the chosen partner center within 48–72 hours.
• A structured teleconsultation is arranged: Heart Team preliminary opinion, provisional device selection, access route suitability, and cost estimate provided.
• GAF Healthcare initiates e-Medical Visa application (India) or entry visa facilitation (UAE) and coordinates travel logistics.

PHASE 2 — ARRIVAL & PRE-PROCEDURAL WORKUP (Days 1–3 in country):